Barriers and Enablers to Diabetes Technologies Use Among Individuals With Type 1 Diabetes: A Scoping Review Authors: Laura Palermo, Joyeuse Senga, Patience Fakembe, Xi Zhu, Chris Walsh, Brenna Leslie, Rayzel Shulman, Justin Presseau, Maman Joyce Dogba, Ananya Banerjee, Rémi Rabasa‐Lhoret, Meranda Nakhla, Anne‐Sophie Brazeau, Leif Erik Lovblom, Holly O Witteman, Lorraine L Lipscombe, Alanna Weisman Published: 2026 ABSTRACT ABSTRACTBackgroundAdvanced diabetes technologies are standard of care for people with Type 1 diabetes (T1D). However, inequitable access contributes to disparities in outcomes.PurposeTo characterise barriers and enablers to the use of advanced diabetes technologies among individuals with T1D and to synthesise these determinants using the Theoretical Domains Framework.Data SourcesEMBASE, Cochrane, PubMed, and MEDLINE were systematically searched from January 1, 2000, to September 30, 2025.Study SelectionWe included studies of any design examining characteristics associated with the use of insulin pumps, continuous glucose monitors (CGM), or automated insulin delivery (AID) in T1D.Data ExtractionTwo reviewers independently screened and extracted data using a standardised tool. Determinants were categorised as non‐modifiable or potentially modifiable barriers or enablers. Modifiable determinants were mapped to TDF domains to enable theory‐informed synthesis.Data SynthesisOf 3081 citations identified, 303 studies (1 864 469 participants) were included. Non‐modifiable determinants most frequently associated with technology use included racial/ethnic minority status (n = 90), age (n = 53), sex (n = 36), and socioeconomic status (n = 40). Potentially modifiable determinants clustered primarily within six TDF domains, most commonly Environmental Context and Resources, Social Influences, Knowledge, Skills, Beliefs about Consequences, and Emotions. Within these domains, key barriers included financial constraints (n = 117), provider gatekeeping and clinic processes (n = 43), and physical burden or body image concerns (n = 41). Key enablers included supportive patient–provider relationships and shared decision‐making (n = 42), patient education and knowledge of device benefits (n = 40), and proactive provider engagement (n = 24).LimitationsA large proportion of abstracts (35.3% overall; 70.6% of interventions), potential publication bias, exclusion of grey literature, predominance of US‐based studies (62.4%), and few AID‐only studies (6.9%) may limit generalisability.ConclusionsBarriers to diabetes technology use map to key TDF domains, with structural factors predominating. Multilevel interventions targeting health system processes, provider practices, and education are needed to improve equitable uptake.Keywords: barriers, continuous glucose monitoring (CGM), insulin pump therapy, type 1 diabetes For people and families living with Type 1 diabetes (T1D), maintaining near‐normal glucose levels while minimising hypoglycaemia is critical to reducing the risk of diabetes complications [1]. However, attainment of target glucose levels is burdensome and challenging [2, 3]. Technologies have emerged as promising tools for optimising glucose management and reducing burden. Automated insulin delivery (AID) systems in particular, which combine insulin pump therapy with continuous glucose monitoring (CGM) and predictive algorithms, have demonstrated substantial benefits for improving glycaemic outcomes as well as patient‐reported outcome measures such as quality of life [4, 5, 6]. Recently, several international organisations and guidelines have recommended AID systems as the standard of care in T1D for all who are willing and able to use these technologies [7, 8]. With AID becoming the standard of care for T1D management, health systems must prioritise universal, equitable access and uptake of these technologies. However, lower uptake and utilisation of technologies among socially disadvantaged individuals with T1D (e.g., racial or ethnic minority or low socioeconomic status) are persistent across many health systems and regions. Compared to individuals with T1D who are not socially disadvantaged, those living with social disadvantage have higher HbA1c levels, more frequent hospitalisations for diabetic ketoacidosis and severe hypoglycaemia, and higher rates of long‐term diabetes complications [2, 9, 10, 11, 12, 13, 14, 15, 16]. Although these differences in health outcomes arise from multiple factors, unequal uptake and sustained use of advanced diabetes technologies is a key contributor [16]. While financial barriers are certainly present, disparities persist even in the setting of universal funding programs [17, 18, 19, 20]. Additional factors contributing to disparities include negative experiences with healthcare providers, mistrust, implicit bias, low health literacy among patients, language barriers, administrative burdens, provider gatekeeping, and suboptimal access to specialists [21, 22, 23, 24, 25, 26, 27]. Importantly, inequities in access to diabetes technologies persist even within publicly funded health systems. For example, population‐based data from the United Kingdom demonstrate that individuals living in areas of greater socioeconomic deprivation are substantially less likely to access insulin pumps and CGM, despite universal coverage; however, when access is achieved, glycaemic outcomes improve to a similar extent across socioeconomic groups [28]. These findings underscore that financial coverage alone is insufficient and that additional social and structural determinants shape equitable uptake and use. In contrast, there are potential facilitators, such as targeted initiatives and strategies entailing expanded insurance coverage and patient and provider education, that offer promise in reducing disparities in technology uptake and use [29, 30, 31]. Although numerous studies have identified and examined barriers, enablers, and disparities in the use of advanced diabetes technologies, the evidence remains fragmented. We conducted a scoping review to comprehensively synthesise the existing literature on the barriers and enablers to the uptake and use of advanced diabetes technologies among individuals with T1D. A scoping review was selected because of the emerging and interdisciplinary evidence base, broad research question, and anticipation of diverse study designs including both quantitative and qualitative methods. Methods A scoping review was conducted following the JBI manual for Evidence Synthesis, and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta‐Analysis Extension for Scoping Reviews (PRISMA‐ScR) guidelines [32]. A review protocol was created prior to study screening and uploaded to the Open Science Framework (OSF) on November 10, 2023. The protocol is publicly accessible at DOI: 10.17605/OSF.IO/AB8M3. The most recent update to the protocol was made on June 6, 2024. This scoping review was informed by the Theoretical Domains Framework (TDF), an integrative framework developed to synthesise constructs from multiple behaviour change theories into a comprehensive set of domains representing determinants of behaviour [33, 34]. The TDF encompasses cognitive, affective, social, and environmental influences on behaviour and has been widely applied in implementation science to identify barriers and enablers and inform intervention design. Mapping identified determinants associated with technology use or non‐use to TDF domains supported structured interpretation of findings, facilitated comparison across heterogeneous study designs, and enabled identification of modifiable mechanisms that may be targeted in future equity‐focused interventions. Search Strategy The search strategy was developed in consultation with two librarians (C.W. and B.L.) and adapted for each database and/or information source (Appendix I and II). The search strategy included controlled vocabulary and key words including ‘Type 1 Diabetes’ AND ‘Insulin pump’ OR ‘Continuous Glucose Monitor’ OR ‘Artificial OR Bionic Pancreas’ AND ‘Vulnerable populations’ OR ‘Social determinants of health’ OR ‘Health literacy’. An initial limited search of Scopus was undertaken in November 2023 to identify articles on the topic. The text words contained in the titles and abstracts of relevant articles, along with the index terms used to describe them, were used to develop a full search strategy. Published studies were located in the following databases: EMBASE, Cochrane, PubMed (non‐MEDLINE records only), and MEDLINE. The searches in Medline and Cochrane were run concurrently. The searches were updated in May 2024 and September 2025. In addition, the reference list of all included sources of evidence were reviewed to identify additional relevant studies. Eligibility Criteria All study designs were eligible for inclusion, including interventional, observational, qualitative studies, and review articles. Inclusion criteria were studies focusing on individuals with T1D and factors associated with the initiation, use, or lack thereof of insulin pumps, CGM, and/or AID. No restrictions were placed on age, language, or geographic location. The search was restricted to articles published since 2000, as technologies have evolved substantially and technologies more than 25 years old would not be clinically relevant. Articles were excluded if they exclusively focused on individuals with Type 2 diabetes (T2D), technologies other than insulin pumps, CGM, or AID, or solely reported effectiveness outcomes such as glycaemic measures, treatment satisfaction, or quality of life. When review articles were included, primary studies appearing both as individual articles and within reviews were counted only once, with data extracted from the original primary studies to avoid duplication. Selection of Sources of Evidence All identified citations were collated and uploaded into the Covidence software platform and duplicate articles were removed. Four independent reviewers (J.S., L.P., P.F., and X.Z.) participated in a two‐stage selection process. The first stage involved screening all titles and abstracts for assessment against the inclusion criteria. In the second stage, articles underwent a full‐text review to determine their final inclusion or exclusion. In both stages, all articles were screened independently by two reviewers. A third reviewer was consulted to resolve any conflicts and reach a consensus if disagreements arose. Data Extraction and Analysis Four reviewers independently extracted data using a standardised tool in Covidence, piloted on five studies. One reviewer extracted and a second independently verified data for accuracy. Extracted data was downloaded from Covidence into a Microsoft Excel file and included publication details, article type, study design, study objectives, sample size, participant characteristics, and key findings relevant to the review, such as the type of technology studied, reported disparities, as well as intervention description and outcomes (if applicable). A weighted mean kappa was calculated for all reviewers at both stages of the article selection process to assess inter‐rater reliability. Articles were categorised based on study design, including interventional studies [non‐randomised experimental studies, quality improvement (QI) studies, randomised controlled trials (RCT)], qualitative studies, observational studies (cross‐sectional studies, mixed methods, observational studies, prospective observational studies, retrospective chart reviews, retrospective cohort studies, secondary analyses of RCTs, serial cross‐sectional studies), and other studies (commentaries, letters, position statements, reviews). Articles categorised as ‘other’ primarily contributed conceptual insights, policy context, and expert perspectives on barriers and facilitators, which were used to complement empirical findings from observational, qualitative, and interventional studies. Determinants of technology use (barriers and enablers) were identified for each article and tabulated across all articles. Each article could contribute multiple barriers or enablers, but a specific barrier or enabler was only counted once per article. For qualitative and observational studies, barriers and enablers to technology use were identified, whereas for interventional studies, only enablers (successful components of interventions) were identified. Barriers were defined as any patient‐, provider‐, or system‐level characteristics that were associated with reduced uptake, discontinuation, or negative experience with advanced diabetes technologies, and enablers as characteristics associated with greater uptake, sustained use, or positive experiences. Determinants were subsequently categorised as potentially modifiable or non‐modifiable to distinguish factors amenable to intervention from fixed sociodemographic or clinical characteristics. Potentially modifiable determinants were organised using the Theoretical Domains Framework (TDF) with decision rules guiding classification (Table S1). When a potentially modifiable determinant could map to more than one TDF domain, it was assigned to the domain that best reflected its primary underlying mechanism, informed by existing TDF literature and team consensus. In line with PRISMA‐ScR recommendations, no formal quality or risk‐of‐bias assessment of included studies was conducted. However, to support interpretation of findings, we categorised barriers and enablers by publication type (full‐text articles vs. conference abstracts) to account for differences in methodological detail and reporting, as presented in Tables 2 and 3. Frequencies were calculated as the number of times a barrier or enabler was identified across included studies. TABLE 2Barriers and enablers to initiation and use of diabetes technologies, organised by the Theoretical Domains Framework. a TDF domainFactorClassification (barrier/enabler)Frequency identified in full‐textFrequency identified in abstractOverall frequencyEnvironmental Context and Resources326Financial limitations (insurance gaps, unaffordability, low income)Barrier8037117Clinic/Provider Practices: provider gatekeeping and clinic ‘readiness’ criteria (e.g., based on glycaemic control or perceived self‐management skills; paperwork constraints)Barrier35843Location: rural vs. urban residence, site/region differences, variable reimbursement/coverage across settingsBarrier25530Technology functionality and technical reliability issues: signal loss, reliability concerns, component compatibility, delivery/replacement challengesBarrier141024Limited clinic time and training capacity for technology education: time constraints for teaching, limited staff/expertise, limited support with paperwork/documentationBarrier13619Alarm fatigue and disruptive alertsBarrier17219Structured clinical workflows and standardised documentationEnabler61117Favourable technology features: discreteness, reduced fingersticks, integration with other devicesEnabler14115Dedicated technology pathways and quality improvement programsEnabler6511Supported technology trials and initiation processesEnabler549Advocacy initiatives to improve access or coverage (e.g., Medicaid or other payer initiatives)Enabler268Insurance navigation and financial coverage supportEnabler617Telemedicine and virtual care accessEnabler437Beliefs about Consequences131Physical burden and body image concerns (visibility, discomfort, attachment/skin issues, interference with activities or sleep)Barrier33841Misconceptions or perceived lack of benefit/added burden of technology (e.g., resistance, dislike of more diabetes information, perceived extra burden)Barrier26733Concerns about technology accuracy and reliability (mistrust)Barrier24933Perceived improvements in glycaemic control and quality of lifeEnabler19524Knowledge102Patient education and knowledge of technology benefitsEnabler241640Inadequate technology knowledge for patient and/or parents, poor health literacy, time constraints for learningBarrier13619Provider education and technology competencyEnabler121123Information overload and difficulty interpreting technology dataBarrier15520Social Influences101Supportive patient–provider relationships and shared decision‐making (individualised care, collaborative decision‐making, provider optimism/engagement)Enabler251742Lack of family or provider supportBarrier18725Frequent and proactive provider contact (e.g., frequent follow‐up, proactive outreach or dose adjustments between visits)Enabler111324Limited shared decision‐making or unequal treatment responsibilitiesBarrier415Active provider encouragement and endorsement (provider support and encouragement to initiate/sustain technology use)Enabler505EmotionEmotional burden (fear, stigma, frustration)Barrier29837SkillsPerceived insufficient parental/patient skills/capability for technology initiation or useBarrier14519 a Barriers and enablers with a frequency of ≥ 5 were included. No barriers/enablers with a frequency of ≥ 5 were mapped to the remaining eight TDF domains. Barriers and enablers to initiation and use of diabetes technologies, organised by the Theoretical Domains Framework. a Barriers and enablers with a frequency of ≥ 5 were included. No barriers/enablers with a frequency of ≥ 5 were mapped to the remaining eight TDF domains. TABLE 3Non‐modifiable determinants associated with diabetes technology initiation and use. a DeterminantFrequency identified in full‐textFrequency identified in abstractsOverall frequencyRacial or ethnic minority status603090Age46753Socioeconomic status281240Sex31435Diabetes duration15217Baseline haemoglobin A1c11011Non‐English language/limited English proficiency6511Immigrant status9110Family structure and caregiving context808Baseline frequency of blood glucose monitoring606Clinical complexity and comorbid health burden (comorbidities and diabetes‐related complications; acute metabolic events; mental health comorbidity)808 a Non‐modifiable determinants with a frequency of ≥ 5 were included. Non‐modifiable determinants associated with diabetes technology initiation and use. a Non‐modifiable determinants with a frequency of ≥ 5 were included. Results The search strategy resulted in 3081 citations. After full text review, 303 articles were ultimately included (Figure 1). The most common reasons for exclusion at the full‐text stage were studies not addressing disparities, barriers, or enablers (n = 33) or not containing enough relevant information (n = 25) (Figure 1). Inter‐rater agreement for selection of articles at the title and abstract and full‐text review stages, calculated using a weighted mean Cohen's kappa, were defined as substantial (κ = 0.75) and moderate (κ = 0.41), respectively [35]. PRISMA diagram. Characteristics of Articles The summarised characteristics of all included articles are reported in Table 1, and details for each individual article are presented in Table S2. Most articles were full‐text manuscripts (n = 157, 51.8%), primarily authored or conducted in the US (n = 189, 62.4%), and published between 2019 and 2025 (n = 244, 80.5%). Cross‐sectional studies (n = 121, 39.9%) represented the largest study design category. The largest categories for number of participants per study were 101 to 1000 (n = 62, 20.5%) and 1001 to 10 000 (n = 57, 18.8%). There was similar representation of studies focused on adults (> 19 years; n = 87, 28.7%), children (≤ 19 years; n = 84, 27.7%), and both (n = 75, 24.8%). CGM (n = 90, 29.7%), insulin pumps (n = 73, 24.1%), and multiple devices (n = 117, 38.6%) were the focus of most studies, while AID was infrequently the sole focus (n = 21, 6.9%). Observational studies consistently quantified disparities in technology uptake by race/ethnicity, insurance, income, geography, and neighbourhood deprivation. Lower uptake of diabetes technologies among racial or ethnic minority groups were identified for non‐Hispanic Black and Hispanic populations in the United States, Māori and Pacific peoples in New Zealand, and ethnic minority groups in the United Kingdom. Qualitative studies often focused on underrepresented groups and described financial barriers, provider gatekeeping, stigma, and physical burden of device wear. In contrast, demographic reporting in interventional studies was more limited, and representation of disadvantaged populations was less consistently described. TABLE 1Characteristics of included articles.CharacteristicArticles (n = 303)%Type of articleAbstract10735.3%Brief Report20.7%Commentary113.6%Full‐Text15751.8%Letter31.0%Position Statement10.3%Review216.9%Thesis10.3%Country of originAustralia41.3%Canada82.6%China10.3%Colombia20.7%Chile20.7%Denmark10.3%France10.3%Germany113.6%Ireland51.7%Italy10.3%Japan20.7%New Zealand82.6%Poland10.3%South Africa10.3%South Korea10.3%Turkey51.7%UK268.6%US18962.4%Multiple196.3%Not reported/applicable155.0%Study designCross‐sectional12139.9%Mixed methods51.7%Non‐randomised experimental175.6%Observational51.7%Prospective observational62.0%QI3210.6%Qualitative3611.9%RCT20.7%Retrospective chart review103.3%Retrospective cohort237.6%Secondary analysis of RCT31.0%Serial cross‐sectional82.6%Not reported/applicable3511.6%Number of participants< 504514.9%50–100289.2%101–10006220.5%1001–10 0005718.8%> 10 0004815.8%Not reported/applicable6320.8%Age of populationAdults8728.7%Paediatric8427.7%Both7524.8%Not reported/applicable5718.8%Device type studiedAID216.9%CGM9029.7%Insulin pump7324.1%Multiple11738.6%Device not specified20.7%Year of publication2000–200620.7%2007–2012134.3%2013–20184414.5%2019–202524480.5% Characteristics of included articles. Potentially Modifiable Determinants of Diabetes Technology Initiation and Use Across included studies, potentially modifiable determinants of diabetes technology initiation and sustained use clustered within 6 of the 14 TDF domains. Results are summarised in Table 2. Barriers were identified more frequently than enablers overall, with factors spanning environmental, social, cognitive, emotional, knowledge‐based, and skill‐related domains. Environmental Context and Resources Environmental factors were the most frequently represented determinants. Financial barriers, including insurance gaps, unaffordability, and low income, were the single most commonly reported factor across all domains. Features of care delivery also emerged prominently, including provider gatekeeping practices, restrictive clinic ‘readiness’ criteria, and geographic disparities in access. Device‐related issues (e.g., technical reliability, alarm burden) and limited clinic capacity for training or follow‐up were also recurrent themes. In contrast, environmental enablers reflected system‐level supports that facilitated access and uptake. Structured workflows, standardised documentation, dedicated technology pathways, quality improvement initiatives, supported initiation processes, and insurance navigation supports were associated with greater technology use. Telemedicine and virtual care access were also described as facilitating engagement, particularly where in‐person access was constrained. Social Influences Supportive patient–provider relationships and shared decision‐making were among the most frequently identified enablers across all domains. Frequent and proactive provider contact and explicit endorsement of technology also promoted uptake. Conversely, lack of family or provider support and limited shared decision‐making were described as barriers. Beliefs About Consequences Concerns regarding physical burden, body image, visibility, accuracy, and reliability of technologies were commonly cited barriers. Misconceptions about limited benefit or added complexity further impeded uptake. In contrast, perceived improvements in glycaemic control and quality of life consistently facilitated initiation and sustained use. Emotions Emotional burden, including overwhelm, anxiety, and distress related to device use, was frequently identified as a barrier. Notably, no emotional determinants were consistently identified as enablers, suggesting that emotional influences predominantly act as barriers rather than facilitators. Knowledge and Skills Knowledge‐related determinants reflected both patient‐ and provider‐level gaps. Adequate patient education regarding device benefits and functionality, as well as provider competency with technologies, were important enablers. Conversely, limited education, low health literacy, time constraints for learning, information overload, and difficulty interpreting device data were recurrent barriers. Within the Skills domain, limited self‐management capacity and challenges related to parental or patient skill acquisition were described as barriers. No skill‐related factors were consistently identified as enablers. Non‐Modifiable Determinants Associated With Diabetes Technology Initiation and Use Non‐modifiable determinants associated with technology initiation and sustained use are summarised in Table 3. Racial and ethnic inequities were the most consistently reported non‐modifiable determinants, with individuals from racial or ethnic minority groups substantially less likely to initiate or sustain use of technologies. Age‐related differences in technology use varied by age comparator groups and region. Most commonly, older age was associated with lower technology use, particularly among older adults. Socioeconomic disadvantage (e.g., deprivation indices, educational attainment, income instability) was similarly associated with lower technology use. Sex‐based differences were reported across settings, although directionality varied. More frequently, male sex was identified as a barrier (n = 28 studies vs. n = 9 studies for female sex as a barrier). Clinical characteristics were less frequently identified than sociodemographic factors but included diabetes duration, baseline glycaemic control, and baseline frequency of blood glucose monitoring. Migration‐related characteristics—including immigrant status and non‐English language or limited English proficiency—were also associated with differential access and use. Family structure and caregiving context, particularly in paediatric populations, were described as influencing technology uptake. Overall, non‐modifiable determinants largely reflected markers of structural inequity and social position. Interventions Addressing Inequitable Technology Uptake or Use A total of 51 interventional studies were identified, with the majority being conference abstracts and quality improvement studies. For the 15 full‐text articles, interventions were predominantly single‐centre and multi‐component in nature, with most combining patient, provider, and system‐level strategies. Common components included patient education, patient support, more frequent contact with providers, and shared decision‐making, provider education, implementation of standardised processes or workflows, and structured identification and management of barriers. Less commonly, interventions incorporated device trials, screening for social determinants of health, advocacy for coverage or access, and virtual care modalities. Ten full‐text studies described dedicated pathways or programs designed to promote adoption and sustained use of CGM and/or insulin pumps, all of which reported improvements in technology uptake. Discussion This scoping review synthesises the multilevel determinants influencing uptake and sustained use of advanced diabetes technologies in T1D, demonstrating that barriers were described more commonly than enablers and cluster within modifiable domains of the TDF. While disparities in technology use are well described, our findings identify the behavioural, social, and structural mechanisms that underpin these inequities. The key implication is that financial coverage alone is insufficient, and improving equitable uptake will require targeted, theory‐informed interventions that address environmental constraints, provider practices, knowledge gaps, and emotional burden. By mapping determinants to TDF domains, this work provides a practical framework to guide the design of interventions aimed at closing persistent gaps in technology use. Across studies, modifiable determinants clustered within environmental, social, and knowledge‐related domains, pointing to the central role of health system organisation and care delivery processes. Although financial barriers were frequently reported, a consistent finding was that expanding insurance coverage alone does not eliminate disparities. Inequities persisted even in settings with universal or publicly funded access, indicating that non‐financial structural factors, including how technologies are offered, provider decision‐making practices, and availability of support for initiation and sustained use, are critical drivers of differential uptake [18, 19, 36]. These findings suggest that policies focused solely on affordability must be complemented by interventions that address the broader context in which care is delivered. Importantly, disparities by race/ethnicity and socioeconomic position appear to be produced through these structural mechanisms rather than attributable to patient‐level factors alone. Evidence across qualitative and observational studies highlights the role of provider gatekeeping, implicit bias, and unequal care processes in shaping access to diabetes technologies [26, 27]. This reframing shifts the focus away from patient characteristics and towards healthcare systems as the focus of intervention. Strategies such as standardised referral pathways, audit and feedback on prescribing patterns, and equity‐focused workflows may help mitigate variability in provider practices and promote more consistent, equitable access. Findings from interventional studies, although limited by study design and many publications being abstracts, support the potential of multi‐component approaches that target patient, provider, and system‐level barriers simultaneously. Common elements of successful interventions included structured workflows, patient education and support, and increased provider engagement. Some studies incorporated culturally sensitive educational materials, including in languages other than English, which positively influenced the uptake and use of diabetes devices [29, 30, 31]. However, few interventions explicitly prioritised equity, and many were resource‐intensive or single‐centre, raising questions about scalability and sustainability. Future research should focus on developing and evaluating theory‐informed, scalable interventions that explicitly target the modifiable determinants identified in this review. The interplay of multiple social and structural determinants further underscores the importance of intersectionality. Individuals experiencing overlapping forms of disadvantage, such as racial/ethnic minority status, low income, and limited access to care, face compounded barriers that are unlikely to be addressed through single‐component interventions [37, 38]. This highlights the need for coordinated, multi‐level strategies that simultaneously address patient, provider, and system‐level factors. Although findings related to sex and gender were less consistent, male sex was more frequently associated with lower technology uptake. Potential explanations include differences in healthcare engagement and perceptions of device burden or visibility, suggesting that future interventions may benefit from incorporating sex‐ and gender‐specific considerations. By conducting a scoping review without age, geographic, or language restrictions, we intended to capture a wide range of studies from across the globe. However, we found that 62.4% of included studies were authored or conducted in the US. Therefore, findings may not be fully generalisable to countries with different health system structures. Greater representation of studies from other countries and publicly funded health systems is needed. In addition, we found only 6.9% of studies focused solely on AID. Because most evidence pertains to CGM and pump‐only systems, barriers and enablers identified in this review may not fully reflect challenges unique to AID, such as device connectivity, algorithm trust, and interoperability. As AID is increasingly becoming the standard of care for T1D [7, 8], future studies should focus specifically on barriers and enablers to uptake and sustained use of AID, and to explore if they differ from those for CGM and/or insulin pump therapy or are less pronounced when not used in automation. There are some limitations to our scoping review. First, 35.3% of all included articles and 70.6% of interventional studies were abstracts, with limited detail available. Second, our findings may be affected by publication bias, as highlighted by the lack of any intervention studies that were not successful. Third, our review focused solely on peer‐reviewed literature, excluding potentially relevant grey literature. Fourth, studies requiring active participant consent may under‐represent socially disadvantaged and minoritised populations compared with retrospective real‐world studies, which have implications for generalisability and may underestimate the magnitude of disparities. Finally, as is standard for scoping reviews, assessment of quality of included studies was not performed. In conclusion, this scoping review demonstrates that inequities in the uptake and use of advanced diabetes technologies are driven primarily by modifiable structural and health system factors. Addressing these determinants through targeted, theory‐informed, and scalable interventions is essential to ensure that advances in diabetes technology translate into equitable improvements in outcomes for all individuals with T1D. Author Contributions L.P., A.W., and J.S. designed the study. J.S. developed the study protocol. C.W. and B.L. designed and conducted the literature search strategy. L.P. drafted the initial version of the manuscript. L.P., J.S., P.F., and X.Z. reviewed eligible studies and performed data extraction. All authors contributed to the study design, critically reviewed the manuscript, and provided feedback on its intellectual content. All authors approved the final version for submission. Funding This scoping review is a component of the Achieving Equitable Uptake and Use of Diabetes Technologies. Among Adults with Type 1 Diabetes (EQUAT1D) project funded by Diabetes Canada, Canadian Institute of Health Research (CIHR), and Breakthrough T1D Canada. The funders had no role in study design, data collection, analysis, interpretation, or manuscript preparation. Disclosure Dr. Alanna Weisman is the guarantor of this work and, as such, had full access to all the data included in the scoping review and takes responsibility for the integrity of the review process and the accuracy of the data synthesis. Conflicts of Interest The following authors have conflicts of interest to disclose: L.L.L. receives salary support as the executive director of the Novo Nordisk Network for Healthy Populations at University of Toronto, which is partly funded through a donation from Novo Nordisk Canada to University of Toronto. R.S. has received advisory board and speaking fees from Dexcom Canada. A.‐S.B. is a research scholar of Fonds de recherche du Québec‐Santé and has received speaker fees from Dexcom. H.O.W. holds the Canada Research Chair in Human‐Centred Digital Health. R.R.‐L. has received research grants from Astra‐Zeneca, Eli Lilly, Merck, Novo‐Nordisk, Sanofi‐Aventis and Vertex Pharmaceutical; has been a consultant or member on advisory panels for Abbott, Amgen, Astra‐Zeneca, Bayer, Carlina Technology, Dexcom, Eli Lilly, HSL Therapeutics, Insulet, Janssen, Medtronic, Merck, Novo‐Nordisk, Pfizer and Sanofi‐Aventis; and has received honoraria for conferences by Abbott, Astra‐Zeneca, CMS Canadian Medical & Surgical Knowledge Translation Research group, CPD Network, Dexcom, Eli Lilly, Janssen, Medtronic, Merck, Novo‐Nordisk, Sanofi‐Aventis and Vertex Pharmaceutical. R.R.‐L. also benefits from unrestricted grants for clinical and educational activities from Abbott, Eli Lilly, Medtronic, Merck, Novo Nordisk and Sanofi‐Aventis and holds intellectual property in the field of Type 2 diabetes risk biomarkers, catheter life and the closed‐loop system. Supporting information Table S1: Theoretical Domains Framework (TDF) Decision Rules Used to Classify Modifiable Factors as Barriers or Enablers. Table S2: Characteristics of individual articles. Intervention‐Based Studies (Quality Improvement, Non‐Randomised Experimental, RCT). Data Availability Statement All data is available in Table S2. Any further information may be requested to the corresponding author. References Associated Data Supplementary Materials Table S1: Theoretical Domains Framework (TDF) Decision Rules Used to Classify Modifiable Factors as Barriers or Enablers. Table S2: Characteristics of individual articles. Intervention‐Based Studies (Quality Improvement, Non‐Randomised Experimental, RCT). Data Availability Statement All data is available in Table S2. Any further information may be requested to the corresponding author.